Sandra Milev - Publications, H-index & Citations

Back

Sandra Milev

Evidera

5H-index

29Paper Count

146Citation Count

Published Papers 8

Publication Date

Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England

Oncology and Therapy

IF3.2

2025-11-15

OAAI

Joel Russell; Mack Harris; Ariel Sun; Benjamin White; Thor-Henrik Brodtkorb; James Brockbank; Stefano Lucherini; Lien Vo; Sandra Milev

Save

Cost-effectiveness of perioperative nivolumab plus neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States

JOURNAL OF MEDICAL ECONOMICS

IF3

2025-04-25

OAAI

White, Benjamin; Harris, Mack; Villacorta, Reginald; Sun, Ariel; Milev, Sandra; Lucherini, Stefano

Save

Untitled Reply

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2022-12-15

OAAI

Kieffer, Alexia; Beuvelet, Matthieu; Sardesai, Aditya; Musci, Robert; Milev, Sandra; Lee, Jason K. H.

Save

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2022-08-15

OAAI

Kieffer, Alexia; Beuvelet, Matthieu; Sardesai, Aditya; Musci, Robert; Milev, Sandra; Roiz, Julie; Lee, Jason K. H.

Save

BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES

VALUE IN HEALTH

IF6

2019-05-01

OAAI

Foster, S. A.; Milev, S.; Hoog, M.; Mason, O.; Sardesai, A.; Hasan, A.; Marrone, C.

Save

Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines

VALUE IN HEALTH

IF6

2019-02-01

OAAI

Betts, Marissa Blieden; Milev, Sandra; Hoog, Meredith; Jung, Hyosung; Milenkovic, Dusan; Qian, Yi; Tai, Ming-Hui; Kutikova, Lucie; Villa, Guillermo; Edwards, Christine

Save

ASSESING PARAMETER IMPORTANCE IN HEALTH ECONOMICS MODELS. CAN WE MAKE IT FASTER?

VALUE IN HEALTH

IF6

2013-05-01

OAAI

Milev, S.; Coyle, D.

Save

COSTS OF TUMOR NECROSIS FACTOR BLOCKERS PER TREATED PATIENT ACROSS ADULT INDICATIONS USING REAL-WORLD DATA IN US COMMERCIALLY-INSURED POPULATION

VALUE IN HEALTH

IF6

2011-11-01

OAAI

Schabert, V; Gandra, S. R.; Watson, C.; Fox, K. M.; Yeaw, J.; Goodman, S.; Milev, S.; Harrison, D. J.

Save

Research Directions